Starpharma presenting at Bell Potter LifeScience Conference
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel study demonstrates reduced risk of recurrent BV
- Starpharma Dendrimer-Docetaxel eliminates neutropenia
- SPL Signs Priostar Agrochemical Partnership with Gowan
- SPLs dendrimer a potential viral conjunctivitis treatment
- Reduced neurotoxicity - SPLs dendrimer enhanced oxaliplatin
Later from Starpharma
- Reports rapid advancement of drug delivery program
- Response to an ASX price query
- SPL Commences pivotal phase 3 VivaGel BV treatment trials
- SPL receives FDA Special Protocol Assessment for BV Phase 3
- SPL`s dendrimers improve efficacy of docetaxel in animals
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma